Jonathan D Breshears1, Joseph Chang2, Annette M Molinaro1,3, Penny K Sneed4, Michael W McDermott1, Aaron Tward2, Philip V Theodosopoulos1. 1. Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. 2. Department of Otolaryngology, Head and Neck Surgery, University of California, San Francisco, San Francisco, California. 3. Department of Epidemiology and Biostatistics, Uni-versity of California, San Francisco, San Francisco, California. 4. Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND: The optimal observation interval after the radiosurgical treatment of a sporadic vestibular schwannoma, prior to salvage intervention, is unknown. OBJECTIVE: To determine an optimal postradiosurgical treatment interval for differentiating between pseudoprogression and true tumor growth by analyzing serial volumetric data. METHODS: This single-institution retrospective study included all sporadic vestibular schwannomas treated with Gamma Knife radiosurgery (Eketa AB, Stockholm, Sweden; 12-13 Gy) from 2002 to 2014. Volumetric analysis was performed on all available pre- and posttreatment magnetic resonance imaging scans. Tumors were classified as "stable/decreasing," "transient enlargement", or "persistent growth" after treatment, based on incrementally increasing follow-up durations. RESULTS: A total of 118 patients included in the study had a median treatment tumor volume of 0.74 cm3 (interquartile range [IQR] = 0.34-1.77 cm3) and a median follow-up of 4.1 yr (IQR = 2.6-6.0 yr). Transient tumor enlargement was observed in 44% of patients, beginning at a median of 1 yr (IQR = 0.6-1.4 yr) posttreatment, with 90% reaching peak volume within 3.5 yr, posttreatment. Volumetric enlargement resolved at a median of 2.4 yr (IQR 1.9-3.6 yr), with 90% of cases resolved at 6.9 yr. Increasing follow-up revealed that many of the tumors initially enlarging 1 to 3 yr after stereotactic radiosurgery ultimately begin to shrink on longer follow-up (45% by 4 yr, 77% by 6 yr). CONCLUSION: Tumor enlargement within ∼3.5 yr of treatment should not be used as a sole criterion for salvage treatment. Patient symptoms and tumor size must be considered, and giving tumors a chance to regress before opting for salvage treatment may be worthwhile.
BACKGROUND: The optimal observation interval after the radiosurgical treatment of a sporadic vestibular schwannoma, prior to salvage intervention, is unknown. OBJECTIVE: To determine an optimal postradiosurgical treatment interval for differentiating between pseudoprogression and true tumor growth by analyzing serial volumetric data. METHODS: This single-institution retrospective study included all sporadic vestibular schwannomas treated with Gamma Knife radiosurgery (Eketa AB, Stockholm, Sweden; 12-13 Gy) from 2002 to 2014. Volumetric analysis was performed on all available pre- and posttreatment magnetic resonance imaging scans. Tumors were classified as "stable/decreasing," "transient enlargement", or "persistent growth" after treatment, based on incrementally increasing follow-up durations. RESULTS: A total of 118 patients included in the study had a median treatment tumor volume of 0.74 cm3 (interquartile range [IQR] = 0.34-1.77 cm3) and a median follow-up of 4.1 yr (IQR = 2.6-6.0 yr). Transient tumor enlargement was observed in 44% of patients, beginning at a median of 1 yr (IQR = 0.6-1.4 yr) posttreatment, with 90% reaching peak volume within 3.5 yr, posttreatment. Volumetric enlargement resolved at a median of 2.4 yr (IQR 1.9-3.6 yr), with 90% of cases resolved at 6.9 yr. Increasing follow-up revealed that many of the tumors initially enlarging 1 to 3 yr after stereotactic radiosurgery ultimately begin to shrink on longer follow-up (45% by 4 yr, 77% by 6 yr). CONCLUSION:Tumor enlargement within ∼3.5 yr of treatment should not be used as a sole criterion for salvage treatment. Patient symptoms and tumor size must be considered, and giving tumors a chance to regress before opting for salvage treatment may be worthwhile.
Authors: Mohamed H Khattab; Neil B Newman; David M Wharton; Alexander D Sherry; Guozhen Luo; Nauman F Manzoor; Alejandro Rivas; L Taylor Davis; Lola B Chambless; Albert Attia; Anthony J Cmelak Journal: J Neurol Surg B Skull Base Date: 2019-06-12
Authors: Daniel E Killeen; Anthony M Tolisano; Brandon Isaacson; J Walter Kutz; Samuel Barnett; Zabi Wardak; Jacob B Hunter Journal: J Neurol Surg B Skull Base Date: 2020-10-05
Authors: Sergio W Guadix; Alice J Tao; Anjile An; Michelle Demetres; Umberto Tosi; Swathi Chidambaram; Jonathan P S Knisely; Rohan Ramakrishna; Susan C Pannullo Journal: Neurooncol Pract Date: 2021-08-13
Authors: Young Goo Kim; Chang Kyu Park; Na Young Jung; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Won Seok Chang Journal: Radiat Oncol Date: 2022-05-07 Impact factor: 4.309
Authors: In-Ho Jung; Kyung Won Chang; So Hee Park; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Won Seok Chang Journal: Sci Rep Date: 2022-08-11 Impact factor: 4.996